Portfolio company
AMiLion AB
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops a nanopore-based sensor platform that measures bioavailable copper levels in body fluids for patients with Alzheimer's, Wilson's, and Menkes diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
AminoSense
This company develops a biosensor platform for real-time amino acid measurement at home to help consumers optimize protein nutrition and metabolic health.
NeuroBionics
This company develops flexible bioelectronic fibers for endovascular neuromodulation to treat neurological and peripheral nerve disorders in patients without requiring invasive open-brain surgery.
Pre Diagnostics
This company develops intracellular blood tests and biomarker analytical services for the early detection of Alzheimer's disease for patients, practitioners and researchers.
Amulet Allergy
This company develops portable sensors and wearable devices that detect food allergens and contaminants for individual consumers and food manufacturers.
AMYL THERAPEUTICS
The company develops pan-amyloid immunotherapies to treat patients with neurodegenerative and rare diseases caused by toxic protein aggregates.
Apieron
This company develops biosensor devices to monitor exhaled nitric oxide for asthma management in patients and clinical settings.
Cytox
This company develops non-invasive genetic tests for Alzheimer's disease risk assessment and patient stratification for clinicians and pharmaceutical researchers.
Neuraworx
This company develops a wearable neurostimulation device that enhances the brain's waste clearance system to treat neurodegenerative diseases and traumatic brain injuries.
